Qiagen N.V. (Qiagen) has appointed Tom Clement as vice president regulatory and clinical affairs of the company, effective January 12, 2009. In his new position, he will direct and coordinate Qiagen's regulatory affairs department and all global activities related to regulatory submissions. Tom Clement joins the company from Roche Molecular Systems, where he was vice president of quality and regulatory.

Prior to Roche, he worked at other diagnostic and medical device companies including Organon Teknika (bioMerieux), Amersham, Biotech Research Laboratories and others.

He holds a Bachelor of Science from the University of Maryland.

“Tom brings more than thirty years of industry experience to QIAGEN”, said Douglas Liu, vice president operations. “He has a proven track record of obtaining U.S. FDA and EU IVD Directive approvals, of which many were first of their kind. Throughout his career, he has demonstrated excellent skills in leadership and in identifying, developing and implementing strategic regulatory and clinical initiatives. As a global leader in molecular diagnostics, QIAGEN has a substantial portfolio of regulated products and is continually widening its scope of submission for approval of its sample and assay technologies in the U.S., Europe and Asia. Tom’s expertise will allow us to further refine and execute our regulatory and clinical affairs strategy which is key to our company’s overall growth.”